key: cord-0829441-7n5va0pr
authors: Ferastraoaru, Denisa; Hudes, Golda; Jerschow, Elina; Jariwala, Sunit; Karagic, Merhunisa; de Vos, Gabriele; Rosenstreich, David; Ramesh, Manish
title: Reply to “Protective effects of eosinophils against COVID-19: More than an ACE(2) in the hole?”
date: 2021-06-07
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.03.018
sha: ce8f5c3965708a5000c21675aebfe3aa432b663b
doc_id: 829441
cord_uid: 7n5va0pr

nan

Reply to ''Protective effects of eosinophils against COVID-19: More than an ACE (2) in the hole?''

To the Editor:

We would like to thank Drake et al 1 for their valuable comment regarding the antiviral effect of eosinophils, which may explain why patients with type 2 high asthma were protected against severe disease (COVID-19) in our study. 2 An important aspect that warrants further investigation is to find a mechanistic explanation for high rates of eosinopenia in hospitalized patients with COVID-19 2-4 and more importantly, how to speed the recovery of eosinophil counts to properly exhibit their antiviral effects.

Previous data show that bacterial, viral, and parasitic acute inflammation is associated with the decrease in circulating eosinophils due to egress inhibition from the bone marrow. 5 Eosinopenia in acute inflammation may also result from distribution of eosinophils in the inflamed tissues 5 ; however, pulmonary samples from individuals with COVID-19 show a predominant mononuclear inflammatory infiltrate (mostly lymphocytic), without the presence of eosinophils. 6 Although eosinopenia is not unique to severe acute respiratory syndrome coronavirus (SARS-CoV-2), it was shown to be more prevalent in COVID-19 than it is in acute influenza infection. 7 Therefore, other mechanisms, perhaps specific to SARS-CoV-2 infection, may explain these findings. It is possible that differences in the cytokine profile of patients with COVID-19 might influence their circulating eosinophils. For example, among the proinflammatory cytokines that are elevated in patients with severe COVID-19, 8 IFN-g/TNF-a have been associated with FasL-induced apoptosis of eosinophils. 9 However, it is not understood which patients are prone to severe disease, eosinopenia, or who are those individuals recovering their eosinophils faster and why. It also remains to be determined if this is an asthma-specific protective effect or a more generalizable finding extending to other conditions. We show in our study that patients with asthma with prior eosinophilia are more likely to recover their circulating eosinophils during COVID-19 hospitalization, and these patients had subsequently less risk of dying from SARS-CoV-2 infection. 2 Therefore, individuals with type 2 high asthma appear to have the advantage of pre-COVID-19 eosinophilia. However, it is unclear if this is their main tool in fighting against severe COVID-19 disease, or if other characteristics of these patients (eg, prior Th2 cytokine predominance that might influence the cytokine milieu released during COVID-19, gender differences, certain medications used for asthma control) are also of importance. 

Eosinophilia in asthma patients is protective against severe COVID-19 illness

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects

Human and mouse eosinophils have antiviral activity against parainfluenza virus

Eosinophils promote antiviral immunity in mice infected with influenza A virus

Anti-IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL). A placebo-controlled, double-blind study

SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

Protective effects of eosinophils against COVID-19: more than an ACE(2) in the hole?

Eosinophilia in asthma patients is protective against severe COVID-19 illness

The role of peripheral blood eosinophil counts in COVID-19 patients

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

Eosinopenia and COVID-19

SARS-CoV-2 infection: the role of cytokines in COVID-19 disease

Effects of interferon-gamma and tumour necrosis factor-alpha on CD95/Fas ligand-mediated apoptosis in human blood eosinophils

Patient variability in severity of COVID-19 disease. Main suspect: vascular endothelium To the Editor: We read with care and interest the original article from Ballow and Haga 1 about the possible explanation for why some